Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid‐Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease
Authors:
Open Access
- 27 October 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 4 (10) , e001675
Abstract
Background: Patients with diabetes mellitus and cardiovascular disease may not achieve adequate low‐density lipoprotein cholesterol ( LDL ‐C) lowering on statin monotherapy, attributed partly to atherogenic dyslipidemia. More intensive LDL ‐C–lowering therapy can be considered for these patients. A previous randomized, controlled study demonstrated greater LDL ‐C lowering in diabetic patients with symptomatic cardiovascular disease who switched from simvastatin 20 mg (S20) or atorvastatin 10 mg (A10) to combination ezetimibe/simvastatin 10/20 mg (ES10/20) therapy, compared with statin dose‐doubling (to S40 or A20) or switching to rosuvastatin 10 mg (R10). The effect of these regimens on novel biomarkers of atherogenic dyslipidemia (low‐ and high‐density lipoprotein particle number and lipoprotein‐associated phospholipase A2 [Lp‐PLA 2 ]) was assessed. Methods and Results: Treatment effects on low‐ and high‐density lipoprotein particle number ( by NMR ) and Lp‐PLA 2 (by ELISA ) were evaluated using plasma samples available from 358 subjects in the study. Switching to ES10/20 reduced low‐density lipoprotein‐particle number numerically more than did statin dose‐doubling and was comparable with R10 (−133.3, −94.4, and −56.3 nmol/L, respectively; P >0.05). Increases in high‐density lipoprotein particle number were significantly greater with switches to ES10/20 versus statin dose‐doubling (1.5 and −0.5 μmol/L; P 0.05). Percentages of patients attaining low‐density lipoprotein particle number levels 2 activity significantly more than did statin dose‐doubling (−28.0 versus −3.8 nmol/min per mL, P 0.05); effects on Lp‐PLA 2 concentration were modest. Conclusions: In diabetic patients with dyslipidemia, switching from statins to combination ES10/20 therapy generally improved lipoprotein subclass profile and Lp‐PLA 2 activity more than did statin dose‐doubling and was comparable with R10, consistent with its lipid effects. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00862251.Keywords
This publication has 60 references indexed in Scilit:
- Changes in Lipoprotein Particle Number With Ezetimibe/Simvastatin Coadministered With Extended‐Release Niacin in Hyperlipidemic PatientsJournal of the American Heart Association, 2013
- Small, Dense LDL Particles Predict Changes in Intima Media Thickness and Insulin Resistance in Men with Type 2 Diabetes and Prediabetes – A Prospective Cohort StudyPLOS ONE, 2013
- 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the AdultCanadian Journal of Cardiology, 2013
- A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular diseaseDiabetes & Vascular Disease Research, 2013
- High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary EventsJACC, 2012
- Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter studyLipids in Health and Disease, 2012
- Clinical implications of discordance between low-density lipoprotein cholesterol and particle numberJournal of Clinical Lipidology, 2011
- Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic SyndromeDiabetes Care, 2009
- Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practiceJournal of Clinical Lipidology, 2008
- Association Between Lipoprotein-Associated Phospholipase A2 and Cardiovascular Disease: A Systematic ReviewMayo Clinic Proceedings, 2007